Table 2.
Incidence of study events in population between SGLT2 inhibitor group and non- SGLT2 inhibitor group
| Non-SGLT2i | SGLT2i | cHR | aHR | |||
|---|---|---|---|---|---|---|
| Pm | Events | Pm | Events | |||
| All-cause death | 733,896 | 666 | 742,390 | 380 | 0.564 (0.497–0.640) | 0.547 (0.482–0.621) |
| NOA | 728,545 | 858 | 737,979 | 721 | 0.832 (0.754–0.919) | 0.830 (0.751–0.916) |
| Atrial fibrillation | 733,017 | 146 | 741,713 | 125 | 0.849 (0.668–1.077) | 0.841 (0.662–1.068) |
| Supraventricular arrhythmias | 733,479 | 67 | 742,054 | 54 | 0.799 (0.558–1.143) | 0.815 (0.570–1.167) |
| Ventricular arrhythmias | 733,651 | 50 | 742,207 | 41 | 0.813 (0.538–1.229) | 0.797 (0.525–1.208) |
aHR, controlled for age, sex, comorbidities, and concurrent medications
Supraventricular arrhythmias include atrial premature complexes and paroxysmal supraventricular tachycardia; ventricular arrhythmias include ventricular tachycardia, ventricular fibrillation and ventricular premature complexes
SGLT2i sodium–glucose co-transporter 2 inhibitor, Pm Person-months, cHR crude hazard ratio, aHR adjusted hazard ratio, NOA new-onset arrhythmias